Gefitinib has been found to improve disease outcomes in non-small cell lung cancer (NSCLC) patients via activation of autophagy, apoptosis, senescence, and cell cycle arrest through augmenting the expression of LC3B-II, cleaved caspase-3, p21, and p53 (Zhu et al., 2015). Here, CASP3 is linked to non-small cell lung carcinoma.